Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Some medtech stocks did decline in 2018, but many more increased in value.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…